AUVI-Q
Peakepinephrine
NDAINTRAMUSCULAR, SUBCUTANEOUSSOLUTION
Approved
Aug 2012
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
13
Mechanism of Action
Adrenergic alpha-Agonists
Pharmacologic Class:
alpha-Adrenergic Agonist
Clinical Trials (5)
Norepinephrine and Vasopressin for Rescue Versus Early Vasopressin for Vasopressor Dependent Sepsis
Started Nov 2024
2,800 enrolled
Septic Shock
Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SUSTAIN)
Started Aug 2024
520 enrolled
Excessive SleepinessShift-work Disorder
Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol
Started Apr 2024
450 enrolled
Binge-Eating Disorder
Progressing TAAR-1, Dopamine, and Norepinephrine in Depression Using Solriamfetol
Started Mar 2024
346 enrolled
Major Depressive Disorder
Study of Inhaled DMC-IH1 and Intramuscular (EpiPen®) Epinephrine in Healthy Male and Female Participants.
Started Oct 2023
24 enrolled
Anaphylactic Reaction
Loss of Exclusivity
LOE Date
Dec 21, 2037
143 months away
Patent Expiry
Dec 21, 2037